Superworth

Ovid Therapeutics EPS OVID

Diluted earnings per share by quarter and over the last twelve months, from 2016.

Last 12 months, to Jun 30, 2026
−$0.25
Latest quarter, Q2 FY26
−$0.08
Fiscal year 2025
−$0.25

Ovid Therapeutics' earnings per share was −$0.25 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.08.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$0.25n/a
FY2024−$0.38n/a
FY2023−$0.75n/a
FY2022−$0.77−144%
FY2021$1.76n/a
FY2020−$1.40n/a
FY2019−$1.58n/a
FY2018−$2.12n/a
FY2017−$4.88n/a
FY2016−$2.28n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.08n/a−$0.25
Q1 FY26−$0.12n/a−$0.23
Q4 FY25$0.12n/a−$0.25
Q3 FY25−$0.17n/a−$0.50
Q2 FY25−$0.06−150%−$0.53
Q1 FY25−$0.14n/a−$0.35
Q4 FY24−$0.13n/a−$0.38
Q3 FY24−$0.20n/a−$0.47
Q2 FY24$0.12n/a−$0.43
Q1 FY24−$0.17n/a−$0.73
Q4 FY23−$0.22n/a−$0.75
Q3 FY23−$0.16n/a−$0.69

Against its peers

Companies in Drug Manufacturers - General nearest Ovid Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
OVIDOvid Therapeutics−$0.25
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
ABUSArbutus Biopharma$0.78
NATRNatures Sunshine Products$1.01+36% a year
AMPHAmphastar Pharmaceuticals$1.70−36% a year
OMEROmeros$1.52
Peer median$0.97

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Ovid Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.